<DOC>
	<DOC>NCT02384512</DOC>
	<brief_summary>End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.</brief_summary>
	<brief_title>Azilect® In Wearing-Off (AIWO)</brief_title>
	<detailed_description>The aim of the non-interventional study is to document efficacy and tolerability of rasagiline as a combination therapy in patients with wearing-off-/End-of-dose fluctuations and the effect of rasagiline on individual wearing-off symptoms, recognized by wearing-off questionnaire 32 (WOQ-32).</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Inclusion: idiopathic Parkinson's disease based on the UK Brain Bank criteria, Wearingoff / endofdose akinesia at least 18 years old, written consent to participate in the study. Exclusion: contraindications according to the SmPC of Azilect®, treatment with Azilect® in the past 3 months and / or suffering from a relevant cognitive impairment and therefore neither understand the patient information, nor can give their consent to participate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>akinesia</keyword>
	<keyword>Azilect®</keyword>
	<keyword>Rasagiline</keyword>
	<keyword>Combination therapy with L-dopa</keyword>
	<keyword>Wearing-off Questionnaire-32</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Daily practice</keyword>
</DOC>